Sonoma Pharmaceuticals (SNOA) Sees Strong Trading Volume
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) saw strong trading volume on Thursday . 5,684,113 shares were traded during trading, an increase of 4,643% from the previous session’s volume of 119,831 shares.The stock last traded at $1.20 and had previously closed at $1.10.
A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 29th. Maxim Group restated a “hold” rating on shares of Sonoma Pharmaceuticals in a report on Friday, November 9th. Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Sonoma Pharmaceuticals in a report on Friday, July 20th. Finally, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th.
The company has a current ratio of 3.80, a quick ratio of 2.84 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $7.32 million, a price-to-earnings ratio of -0.38 and a beta of 1.31.
A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC grew its holdings in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,095 shares of the company’s stock after purchasing an additional 32,180 shares during the quarter. Renaissance Technologies LLC owned about 1.41% of Sonoma Pharmaceuticals worth $226,000 at the end of the most recent reporting period. 11.34% of the stock is currently owned by institutional investors.
About Sonoma Pharmaceuticals (NASDAQ:SNOA)
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.
Recommended Story: What is a capital gain?
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.